Clinical Trial Update: Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update evaluating oral and long-acting injectable cabotegravir and rilpivirine in virologically suppressed children aged 2 to less th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• cabotegravir (cabotegravir)
• rilpivirine (rilpivirine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV-1-infection | Phase 1, Phase 2 | Status: RECRUITING